Literature DB >> 17824496

The evolution and development of insomnia pharmacotherapies.

David N Neubauer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17824496      PMCID： PMC1978321     

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN： 1550-9389            Impact factor:   4.062


× No keyword cloud information.
  11 in total

Review 1.  A new benzodiazepine pharmacology.

Authors:  H Möhler; J M Fritschy; U Rudolph
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

Review 2.  GABA mechanisms and sleep.

Authors:  Claude Gottesmann
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

3.  Tolerance to daytime sedative effects of H1 antihistamines.

Authors:  Gary S Richardson; Timothy A Roehrs; Leon Rosenthal; Gail Koshorek; Thomas Roth
Journal:  J Clin Psychopharmacol       Date:  2002-10       Impact factor: 3.153

Review 4.  Subunit composition, distribution and function of GABA(A) receptor subtypes.

Authors:  W Sieghart; G Sperk
Journal:  Curr Top Med Chem       Date:  2002-08       Impact factor: 3.295

5.  National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005.

Authors: 
Journal:  Sleep       Date:  2005-09       Impact factor: 5.849

6.  Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine.

Authors:  James K Walsh
Journal:  Sleep       Date:  2004-12-15       Impact factor: 5.849

7.  Long-term use of sedative hypnotics in older patients with insomnia.

Authors:  Sonia Ancoli-Israel; Gary S Richardson; Richard M Mangano; Lisa Jenkins; Phil Hall; Walter S Jones
Journal:  Sleep Med       Date:  2005-01-26       Impact factor: 3.492

Review 8.  Ramelteon.

Authors:  Adam McGechan; Keri Wellington
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.

Authors:  Koki Kato; Keisuke Hirai; Keiji Nishiyama; Osamu Uchikawa; Kohji Fukatsu; Shigenori Ohkawa; Yuji Kawamata; Shuji Hinuma; Masaomi Miyamoto
Journal:  Neuropharmacology       Date:  2005-02       Impact factor: 5.250

10.  Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.

Authors:  Andrew D Krystal; James K Walsh; Eugene Laska; Judy Caron; David A Amato; Thomas C Wessel; Thomas Roth
Journal:  Sleep       Date:  2003-11-01       Impact factor: 5.849
View more
  11 in total

1.  Middle-of-the-night hypnotic use in a large national health plan.

Authors:  Thomas Roth; Patricia Berglund; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; Ronald C Kessler
Journal:  J Clin Sleep Med       Date:  2013-07-15       Impact factor: 4.062

2.  Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Patricia Murphy; Margaret Moline; David Mayleben; Russell Rosenberg; Gary Zammit; Kate Pinner; Shobha Dhadda; Quan Hong; Luigi Giorgi; Andrew Satlin
Journal:  J Clin Sleep Med       Date:  2017-11-15       Impact factor: 4.062

3.  Survivorship: sleep disorders, version 1.2014.

Authors:  Crystal S Denlinger; Jennifer A Ligibel; Madhuri Are; K Scott Baker; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H Ku; Elizabeth Kvale; Terry S Langbaum; Kristin Leonardi-Warren; Mary S McCabe; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

4.  Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.

Authors:  Emiliangelo Ratti; David J Carpenter; Stefano Zamuner; Sofia Fernandes; Lisa Squassante; Heidi Danker-Hopfe; Graeme Archer; Jonathan Robertson; Robert Alexander; David G Trist; Emilio Merlo-Pich
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

5.  Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study.

Authors:  Paul K Gross; Rosemary Nourse; Thomas E Wasser
Journal:  J Clin Sleep Med       Date:  2009-02-15       Impact factor: 4.062

6.  Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study.

Authors:  Naohisa Uchimura; Atsushi Kamijo; Takao Takase
Journal:  Ann Gen Psychiatry       Date:  2012-06-25       Impact factor: 3.455

7.  Prevalence and factors associated with off-label antidepressant prescriptions for insomnia.

Authors:  L Leanne Lai; Mooi Heong Tan; Yen Chi Lai
Journal:  Drug Healthc Patient Saf       Date:  2011-07-08

8.  Trial of Zolpidem, Eszopiclone, and Other GABA Agonists in a Patient with Progressive Supranuclear Palsy.

Authors:  Andrew Young Chang; Erica Weirich
Journal:  Case Rep Med       Date:  2014-09-16

9.  Learning and Memory Deficits in Male Adult Mice Treated with a Benzodiazepine Sleep-Inducing Drug during the Juvenile Period.

Authors:  Yusuke Furukawa; Kentaro Tanemura; Katsuhide Igarashi; Maky Ideta-Otsuka; Ken-Ichi Aisaki; Satoshi Kitajima; Masanobu Kitagawa; Jun Kanno
Journal:  Front Neurosci       Date:  2016-07-20       Impact factor: 4.677

10.  Characteristics and Trends in Hypnotics Consumption in the Largest Health Care System in Israel.

Authors:  O Marom; G Rennert; N Stein; K Landsman; G Pillar
Journal:  Sleep Disord       Date:  2016-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.